Can oral GLP-1RAs deliver on the promise of accessible obesity care?
As the race for oral glucagon-like peptide-1 receptor agonists (GLP-1RA) intensifies, physicians hope that their small molecule format will make…
Metabolic Disorders
-
-
Pfizer buys monthly GLP-1RA developer Metsera for $4.9bn
Pfizer has acquired Metsera for $4.9bn, as the drugmaker targets longer-lasting glucagon-like peptide-1 receptor agonists (GLP-1RAs) to cement market share…
-
Sanofi’s Tzield gains approval in China for T1D management
China’s National Medical Products Administration (NMPA) has approved Sanofi’s Tzield (teplizumab), making it the first disease-modifying therapy for autoimmune type…
-
Novo’s Ozempic price cut expected to slow market share erosion
Novo Nordisk’s decision to significantly reduce the price of blockbuster drug semaglutide is expected to slow the shift of patients…
-
WHO adds GLP-1RAs to essential medicines list
The World Health Organisation (WHO) has updated its model list of essential medicines (EML) to include four key obesity and…
-
EMA warns of rise in illegal weight loss drugs marketed online
The European Medicines Agency (EMA) has warned of a sharp rise in illegal medicines being sold under the guise of…
-
Chinese drugmakers prep for looming semaglutide generics horizon
Chinese pharmaceutical companies are eyeing a lucrative commercial market set to materialise upon the patent expiry for Novo Nordisk’s blockbuster…
-
Novo Nordisk enlists srRNA developer Replicate in $550m deal
Novo Nordisk has turned to Replicate Bioscience’s RNA drug platform in a lucrative research collaboration, marking the latest effort by…
-
Eli Lilly eyes orforglipron approval after Phase III diabetes trial success
Although data for Eli Lilly’s orforglipron may have disappointed investors earlier this month, a new release of Phase III data…
-
Madrigal wins European MASH approval as Novo rivalry looms
Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has been approved in Europe for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to…
